Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Emdogain and Straumann Bone Ceramic in Infrabony Defects

This study has been terminated.
(Difficulty to recruit patients fulfilling inclusion criteria)
Sponsor:
Information provided by (Responsible Party):
Institut Straumann AG
ClinicalTrials.gov Identifier:
NCT00906776
First received: May 19, 2009
Last updated: November 20, 2012
Last verified: November 2012
Results First Received: August 30, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Periodontitis
Interventions: Device: Emdogain PLUS
Device: Autogenous bone

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Emdogain PLUS Straumann Emdogain in combination with Straumann BoneCeramic
Autogenous Bone Autogenous bone from the patient

Participant Flow:   Overall Study
    Emdogain PLUS     Autogenous Bone  
STARTED     11     8  
COMPLETED     11     8  
NOT COMPLETED     0     0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Emdogain PLUS Straumann Emdogain in combination with Straumann BoneCeramic
Autogenous Bone Autogenous bone from the patient
Total Total of all reporting groups

Baseline Measures
    Emdogain PLUS     Autogenous Bone     Total  
Number of Participants  
[units: participants]
  11     8     19  
Age  
[units: years]
Mean ± Standard Deviation
  36.9  ± 8.9     31.9  ± 8.6     34.8  ± 8.6  
Gender  
[units: participants]
     
Female     7     4     11  
Male     4     4     8  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Clinical Attachment Level (CAL)   [ Time Frame: Baseline and 12 months ]

2.  Secondary:   Change in Distance Between the Cementum-enamel-junction and the Base of the Vertical Bone Defect   [ Time Frame: Baseline and 6 months ]

3.  Secondary:   Change in Probing Pocket Depth (PPD)   [ Time Frame: Baseline and 12 months ]

4.  Secondary:   Change in Clinical Attachment Level (CAL)   [ Time Frame: Baseline and 6 months ]

5.  Secondary:   Change in Probing Pocket Depth (PPD)   [ Time Frame: Baseline and 6 months ]

6.  Secondary:   Change in Distance Between the Cementum-enamel-junction and the Base of the Vertical Bone Defect   [ Time Frame: Baseline and 12 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Prof Philippe Bouchard
Organization: Rotschild hospital
phone: +33614656947
e-mail: phbouch@noos.fr


No publications provided


Responsible Party: Institut Straumann AG
ClinicalTrials.gov Identifier: NCT00906776     History of Changes
Other Study ID Numbers: CR 01/05
Study First Received: May 19, 2009
Results First Received: August 30, 2012
Last Updated: November 20, 2012
Health Authority: France: Institutional Ethical Committee